Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Revimmune

2006 FOUNDED
M&A STATUS
1-10 EMPLOYEES
M&A LATEST DEAL TYPE
3 FINANCING ROUNDS
Description

Developer of therapies for autoimmune diseases. The Company's lead antineoplastic technology employs a bioengineered poliovirus construct and targets cancerous central nervous cells with great specificity recombinant poliovirus therapy has the potential to significantly reduce or eliminate current chemotherapy side-effects while completely destroying abnormal cancerous tissue.

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Acquirer
Accentia Biopharmaceuticals
Primary Office
  • 324 South Hyde Park Avenue
  • Suite 350
  • Tampa, FL 33606
  • United States

Revimmune Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Revimmune‘s full profile, request access.

Request full access to PitchBook

Revimmune Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Revimmune‘s full profile, request access.

Request full access to PitchBook

Revimmune Executive Team (3)

Name Title Board
Seat
Contact
Info
Frank O'Donnell Director & Officer
Richard Jones Co-Founder
Robert Brodsky Co-Founder